Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-06-07
2000-09-05
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241431, 4241441, 4241531, 4241541, 4241731, 435328, 435332, 435334, 435343, 4353431, 4353432, 435346, 5303873, 53038822, 5303887, 53038873, 53038875, 536 234, 536 235, 536 2353, A61K 39395, C12N 510, C07K 1628, C07H 2102
Patent
active
061138983
ABSTRACT:
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5521288 (1996-05-01), Linsley et al.
Liu et al. "Co-stimulation of murine CD4 T cell growth: cooperation between B7 and heat-stable antigen", Eur. J. Immunol., Nov. 1992, vol. 22, No. 11, pp. 2855-2859 (see entire reference).
Inaba et al. "The tissue distribution of the B7-2 co-stimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro", J. Exp. Med., Nov. 1994, vol. 180, No. 5, pp. 1849-1860 (see entire reference).
Engel et al. "The B7-2 (B70) co-stimulatory molecule expressed by monocytes and actiated B lymphocytes is the CD86 differentiation antigen" Blood, Sep. 1, 1994, vol. 84, No. 5, pp. 1402-1407 (see entire document).
Newman et al. Primatization of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology, Nov. 1992, vol. 10, No. 11, pp. 1455-1460 (see entire reference).
Guinan et al. Blood 84: 3261-3282(1994).
Lenschow etal. Transplantation 60: 1171-1178 (1995).
Perrin et al. J Neuroimmunology 65: 31-39(1996).
Kahan curr. opin. immunol. 4: 553-560 (1992).
Ward et al. Therapeutic immunol. 1: 165-171 (1994).
Linsley et al. Ann Rev. immunol. 11: 191-212(1993).
Cohen Science 262: 844-845 (1993).
Hathcock et al. Science 262: 905-907 (1993).
Freeman et al. Science 262 :907-909(1993).
Freeman et al. Science 262 909-911 (1993).
Newman et al. Biotechnology 10: 1455-1460 (1992).
Paul (ED.) Fundamental immunology Raven Press 1993 p. 242 only.
Anderson Darrell R.
Brams Peter
Hanna Nabil
Heard Cheryl
Shestowsky William S.
Feisee Lila
Gambel Phillip
Idec Pharmaceuticals Corporation
LandOfFree
Human B7.1-specific primatized antibodies and transfectomas expr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human B7.1-specific primatized antibodies and transfectomas expr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human B7.1-specific primatized antibodies and transfectomas expr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2209179